Nektar Therapeutics vs Siga Technologies
Siga Technologies is the larger business, with $94.6m of revenue in fiscal 2025 against $55.2m for Nektar Therapeutics (1.7 times as much). Siga Technologies grew faster (-31.8% against -43.9%). Siga Technologies kept more of each dollar of sales as profit: a net margin of 24.6% against -297.1%. Nektar Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Nektar TherapeuticsNKTR, 2025 | Siga TechnologiesSIGA, 2025 |
|---|---|---|
| Revenue | $55.2m | $94.6m |
| Revenue growth | -43.9% | -31.8% |
| Net income | −$164m | $23.3m |
| Operating margin | -253.7% | 25.1% |
| Net margin | -297.1% | 24.6% |
| Return on equity | — | 11.2% |
| Free cash flow | −$209m | $43.1m |
| Cash | $15.1m | $155m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | $0.60 |
| Dividend yield | — | 20.6% |
| Share buybacks | $0 | $0 |
| Employees | 63 | 49 |
| Market value | $765m | $222m |
| Price vs our value range | — | Below our value range |
| Moat score | 18 (Weak) | 71 (Strong) |
| Insider trades, 12 months | 0 buys, 16 sales | 0 buys, 0 sales |